Advaxis collaborates with UBC to build up live attenuated Listeria vaccines Advaxis.
Tobias Kollmann at the University of British Columbia to build up live attenuated Listeria vaccines for the treating infectious disease and for brand-new dosage forms of Listeria vaccines. Related StoriesNew programmed-death inhibitor display screen assay kit for cancer research studiesVaccines – a needle-free upcoming? An interview with Thomas Dr and Johnston. Kees Leenhouts, MucosisThe same immune-stimulating properties that are under development at Advaxis to build up live Listeria vaccines as safe and effective therapies for the treatment of cancer, may have application for the treating infectious disease also.Interviews had been conducted by phone September 12th-15th, 2013. The margin of error for this survey is +/-3.1 percent at the 95 percent degree of confidence. ‘These results clearly confirm what we’ve known anecdotally for a long time: American health care consumers trust NPs and wish greater usage of the safe, effective solutions they provide,’ stated Ken Miller, Co-President of AANP. ‘This is no surprise given that NP patients have health care outcomes that are in keeping with those of doctors, and that patients consistently, and increasingly, choose NPs as their primary health care provider.’..